Articles producció científica> Medicina i Cirurgia

SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma

  • Identification data

    Identifier: imarina:2309057
    Handle: http://hdl.handle.net/20.500.11797/imarina2309057
  • Authors:

    Rueda Domínguez, Antonio
    Alfaro Lizaso, J
    Cruz Merino, L de la
    Gumà Padró, Josep
    Quero Blanco, Cristina
    Gómez Codina, José
    Llanos Muñoz, Marta
    Martínez Banaclocha, Natividad
    Rodríguez Abreu, Delvys
    Provencio Pulla, Mariano
  • Others:

    Author, as appears in the article.: Rueda Domínguez, Antonio; Alfaro Lizaso, J; Cruz Merino, L de la; Gumà Padró, Josep; Quero Blanco, Cristina; Gómez Codina, José; Llanos Muñoz, Marta; Martínez Banaclocha, Natividad; Rodríguez Abreu, Delvys; Provencio Pulla, Mariano
    Department: Medicina i Cirurgia
    URV's Author/s: Gumà Padró, José
    Keywords: Hashtag Etiqueta «#» @uroweb @residentesaeu @infoAeu
    Abstract: Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease entities; the more commonly diagnosed classical HL and the rare nodular lymphocyte-predominant HL. An accurate assessment of the stage of disease and prognostic factors that identify patients at low or high risk for recurrence are used to optimize therapy. Patients with early stage disease are treated with combined modality strategies using abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, while those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. Brentuximab vedotin should be considered for patients who fail HDCT with ASCT.
    Thematic Areas: Saúde coletiva Oncology Odontología Medicine (miscellaneous) Medicina veterinaria Medicina ii Medicina i Farmacia Engenharias ii Ciências biológicas ii Ciências biológicas i Cancer research Biotecnología
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 1699048X
    Author's mail: jose.guma@urv.cat
    Author identifier: 0000-0001-7541-9832
    Record's date: 2023-04-15
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://pubmed.ncbi.nlm.nih.gov/26497354/
    Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Clinical & Translational Oncology. 17 (12): 1005,1013-1013
    APA: Rueda Domínguez, Antonio; Alfaro Lizaso, J; Cruz Merino, L de la; Gumà Padró, Josep; Quero Blanco, Cristina; Gómez Codina, José; Llanos Muñoz, Marta; (2015). SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma. Clinical & Translational Oncology, 17(12), 1005,1013-1013
    Article's DOI: 10.1007/s12094-015-1429-1
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2015
    Publication Type: Journal Publications
  • Keywords:

    Cancer Research,Medicine (Miscellaneous),Oncology
    Saúde coletiva
    Oncology
    Odontología
    Medicine (miscellaneous)
    Medicina veterinaria
    Medicina ii
    Medicina i
    Farmacia
    Engenharias ii
    Ciências biológicas ii
    Ciências biológicas i
    Cancer research
    Biotecnología
  • Documents:

  • Cerca a google

    Search to google scholar